| scholarly article | Q13442814 |
| P2093 | author name string | Nabila Noor | |
| Howard A. Rockman | |||
| Chetan B. Patel | |||
| P2860 | cites work | Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor | Q43586918 |
| Myocyte adrenoceptor signaling pathways | Q44469057 | ||
| Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure | Q44528608 | ||
| β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure | Q44591642 | ||
| Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol | Q46048377 | ||
| Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies | Q46260678 | ||
| The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation | Q50335944 | ||
| Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death | Q51094115 | ||
| The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts | Q53021334 | ||
| Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy | Q74469678 | ||
| G protein-coupled receptor kinases | Q77366588 | ||
| alpha-Thrombin induces rapid and sustained Akt phosphorylation by beta-arrestin1-dependent and -independent mechanisms, and only the sustained Akt phosphorylation is essential for G1 phase progression | Q77785692 | ||
| Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome | Q81272805 | ||
| Angiotensin II regulates vascular and endothelial dysfunction: recent topics of Angiotensin II type-1 receptor signaling in the vasculature | Q82528563 | ||
| Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes | Q22008730 | ||
| Functional Selectivity and Classical Concepts of Quantitative Pharmacology | Q22242288 | ||
| beta-Arrestin: a protein that regulates beta-adrenergic receptor function | Q24305145 | ||
| Functional specialization of beta-arrestin interactions revealed by proteomic analysis | Q24318455 | ||
| Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 | Q24532154 | ||
| Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments | Q24632640 | ||
| Transduction of receptor signals by beta-arrestins | Q28246395 | ||
| Regulation of receptor trafficking by GRKs and arrestins | Q28268248 | ||
| Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor | Q28572837 | ||
| {beta}-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation | Q28577649 | ||
| Regulation of carbamoyl phosphate synthetase by MAP kinase | Q28578262 | ||
| Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins | Q28578546 | ||
| Beta-arrestins and cell signaling | Q29616793 | ||
| Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor | Q29618735 | ||
| EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF | Q29619098 | ||
| Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. | Q30476292 | ||
| Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol | Q30478644 | ||
| Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis | Q33221546 | ||
| Adrenergic and muscarinic receptors in the human heart | Q33784373 | ||
| Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling | Q33819399 | ||
| beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation | Q33840022 | ||
| Apoptosis in the vasculature: mechanisms and functional importance | Q33959479 | ||
| Teaching old receptors new tricks: biasing seven-transmembrane receptors | Q33985759 | ||
| Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). | Q34093722 | ||
| Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists | Q34122067 | ||
| Cytoplasmic signaling pathways that regulate cardiac hypertrophy | Q34142151 | ||
| Membrane trafficking of G protein-coupled receptors | Q34292577 | ||
| Principles: receptor theory in pharmacology | Q34310931 | ||
| Seven-transmembrane-spanning receptors and heart function | Q34503394 | ||
| Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. | Q34536660 | ||
| Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor | Q34548751 | ||
| beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor | Q34562493 | ||
| Integrating signals from RTKs to ERK/MAPK. | Q34627656 | ||
| Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes | Q35133773 | ||
| Ligand-selective receptor conformations revisited: the promise and the problem | Q35181787 | ||
| Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy | Q35883070 | ||
| Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. | Q35951476 | ||
| A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling | Q36082162 | ||
| Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors | Q36160942 | ||
| ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G | Q36259700 | ||
| When 7 transmembrane receptors are not G protein-coupled receptors | Q36308861 | ||
| Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex | Q36325161 | ||
| Phosphorylation/dephosphorylation of the beta-adrenergic receptor regulates its functional coupling to adenylate cyclase and subcellular distribution | Q36426100 | ||
| Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system | Q36548154 | ||
| New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors | Q36678037 | ||
| Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. | Q36786816 | ||
| Mitogenic signaling pathways induced by G protein-coupled receptors | Q36929839 | ||
| Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. | Q36936400 | ||
| Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and nonsequestering G protein-coupled receptors. | Q37105461 | ||
| Smooth muscle apoptosis and vascular remodeling. | Q37129690 | ||
| The role of calmodulin kinase II in myocardial physiology and disease | Q37192039 | ||
| beta-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. | Q37339073 | ||
| Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration | Q37383096 | ||
| Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. | Q38322188 | ||
| Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. | Q40110003 | ||
| Targeting of diacylglycerol degradation to M1 muscarinic receptors by beta-arrestins | Q40175757 | ||
| G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer | Q40281519 | ||
| Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy | Q40298849 | ||
| Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. | Q40626751 | ||
| Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration | Q40819745 | ||
| Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors | Q40889383 | ||
| Cellular trafficking of G protein-coupled receptor/beta-arrestin endocytic complexes | Q40962075 | ||
| Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. | Q41066099 | ||
| Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors | Q41229236 | ||
| Arrestin orchestrates crosstalk between G protein-coupled receptors to modulate the spatiotemporal activation of ERK MAPK. | Q41865336 | ||
| beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress | Q41917803 | ||
| The Role of a Conserved Region of the Second Intracellular Loop in AT1 Angiotensin Receptor Activation and Signaling | Q42441168 | ||
| Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling | Q42453523 | ||
| Norepinephrine Stimulates Apoptosis in Adult Rat Ventricular Myocytes by Activation of the β-Adrenergic Pathway | Q42539418 | ||
| Arrestin function in G protein-coupled receptor endocytosis requires phosphoinositide binding | Q42667054 | ||
| Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. | Q42800979 | ||
| Growth factor signaling regulates elongation of RNA polymerase I transcription in mammals via UBF phosphorylation and r-chromatin remodeling | Q42804681 | ||
| Arrestin binding to calmodulin: a direct interaction between two ubiquitous signaling proteins | Q42976243 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| targeted therapy | Q492646 | ||
| signal transduction | Q828130 | ||
| P304 | page(s) | 534-541 | |
| P577 | publication date | 2010-11-11 | |
| P1433 | published in | Journal of Molecular and Cellular Cardiology | Q2061932 |
| P1476 | title | Β-arrestin: a signaling molecule and potential therapeutic target for heart failure | |
| β-Arrestin: A signaling molecule and potential therapeutic target for heart failure | |||
| P478 | volume | 51 |
| Q38004211 | An expanded family of arrestins regulate metabolism |
| Q41717344 | Ang-(1-7) is an endogenous β-arrestin-biased agonist of the AT1 receptor with protective action in cardiac hypertrophy |
| Q37642774 | Arrestin-biased AT1R agonism induces acute catecholamine secretion through TRPC3 coupling. |
| Q38835689 | Calcific Aortic Valve Disease: Part 2-Morphomechanical Abnormalities, Gene Reexpression, and Gender Effects on Ventricular Hypertrophy and Its Reversibility |
| Q38759008 | Cardioprotective Action of Ginkgo biloba Extract against Sustained β-Adrenergic Stimulation Occurs via Activation of M2/NO Pathway. |
| Q26771250 | Cardiovascular Dysfunction Following Burn Injury: What We Have Learned from Rat and Mouse Models |
| Q34542663 | Chemerin Elicits Potent Constrictor Actions via Chemokine-Like Receptor 1 (CMKLR1), not G-Protein-Coupled Receptor 1 (GPR1), in Human and Rat Vasculature |
| Q41206403 | Conducting the G-protein coupled receptor (GPCR) signaling symphony in cardiovascular diseases: New therapeutic approaches |
| Q37232104 | Current and future G protein-coupled receptor signaling targets for heart failure therapy |
| Q54505273 | Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure etiology and correlates to clinical variables |
| Q39188093 | Diverse regulation of cardiac expression of relaxin receptor by α1- and β1-adrenoceptors |
| Q38200338 | Employing novel animal models in the design of clinically efficacious GPCR ligands |
| Q38651555 | G protein-coupled receptor kinase 2 promotes cardiac hypertrophy |
| Q38090168 | GPCR biased ligands as novel heart failure therapeutics |
| Q35558398 | Heterotrimeric G protein-mediated signaling and its non-canonical regulation in the heart |
| Q38093445 | Key role of ERK1/2 molecular scaffolds in heart pathology. |
| Q28245037 | Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1 |
| Q51499124 | Measurement of Receptor Signaling Bias |
| Q38096149 | Molecular targeting of Gα and Gβγ subunits: a potential approach for cancer therapeutics |
| Q37470858 | Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms |
| Q41856322 | Novel Strategies for the Treatment of Heart Failure |
| Q36816705 | Regulation of cellular oxidative stress and apoptosis by G protein-coupled receptor kinase-2; The role of NADPH oxidase 4 |
| Q27686777 | Regulators of G-protein signaling in the heart and their potential as therapeutic targets |
| Q35569513 | Simultaneous parasympathetic and sympathetic activation reveals altered autonomic control of heart rate, vascular tension, and epinephrine release in anesthetized hypertensive rats |
| Q37831634 | Taking the heart failure battle inside the cell: small molecule targeting of Gβγ subunits |
| Q37142798 | The β-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium |
| Q64056724 | Therapeutic Potential of Targeting ß-Arrestin |
| Q59807304 | Therapeutic Targets for Treatment of Heart Failure: Focus on GRKs and β-Arrestins Affecting βAR Signaling |
| Q37911818 | Translational Success Stories: Angiotensin Receptor 1 Antagonists in Heart Failure |
| Q84788582 | Where are the new drugs to treat heart failure? Introduction to the special issue on “Key signaling molecules in hypertrophy and heart failure” |
| Q55080676 | You're Not under Arrest: Worry-free with β-arrestin. |
| Q38114223 | β-Arrestins in the immune system |
| Q34603394 | β-Arrestins regulate human cardiac fibroblast transformation and collagen synthesis in adverse ventricular remodeling |
| Q34827316 | β-arrestin2 in Infiltrated Macrophages Inhibits Excessive Inflammation after Myocardial Infarction |
| Q28590593 | β-arrestin2/miR-155/GSK3β regulates transition of 5'-azacytizine-induced Sca-1-positive cells to cardiomyocytes |
| Q38266154 | β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy |
| Q37421052 | βArrestins in cardiac G protein-coupled receptor signaling and function: partners in crime or "good cop, bad cop"? |
Search more.